CD4 and melanoma: Consistent with our results, melanoma patients treated by personalized vaccination with long synthetic neoantigen peptides demonstrated that the proportion of neoantigens stimulating CD4+ T cell responses was higher than that for CD8+ T cell responses, despite the selection of mutations on the basis of predicted presentation by HLA class I [13].